Salveen Richter is a Wall Street analyst working for Goldman Sachs. Salveen has covered 43 stocks with a 41.67% success rate and an average return of 0.47%.

Salveen Richter is a 4.41-star Wall Street Analyst at Goldman Sachs. Salveen Richter's focuses on the Healthcare sector and covers 84 stocks with a 40.86% success rate.

Nov 27, 2024 · Salveen Richter has given his Buy rating due to a combination of factors including the promising results from Amgen’s Phase 2 obesity study of MariTide. The study showed an impressive average...

6 days ago · Analyst Salveen Richter, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 64.8% that have a potential upside of 34.24% achieved within 268 days. Salveen Richter ’s has documented …

Mar 23, 2022 · In the latest episode of Exchanges at Goldman Sachs, Salveen Richter, Lead Analyst for the U.S. Biotechnology Sector in Goldman Sachs Research, explains how new innovations in gene editing are transforming the future of medicine and the greater biotech investment landscape.

Apr 12, 2018 · Analyst Salveen Richter and colleagues laid it out: The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene...

Jan 3, 2024 · Goldman Sachs analyst Salveen Richter maintained a Buy rating on Agios Pharma (AGIO – Research Report) today. The company’s shares opened today at $23.58. According to TipRanks, Richter is a...

Mar 23, 2022 · So I've asked Salveen Richter, our lead biotechnology research analyst in the US, to join us to walk through the latest developments, the most promising applications, and the outlook for broader adoption. Salveen, welcome to the program. Allison, thanks for having me. So let's start with the basics.

Salveen Richter is an analyst at Goldman Sachs. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected...